Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 27

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Pleural mesothelioma

Recruiting

Study on the Use of 68Ga-FAPI-46 and Fludeoxyglucose (18F) for Diagnosing Pleural Mesothelioma in Patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Aalborg University Hospital

Non-small cell lung cancer

Recruiting

Study of Cemiplimab, Carboplatin, and Paclitaxel for Adults with Operable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Non-small cell lung cancer

Recruiting

Study on Pembrolizumab and Chemotherapy with Radiation for Advanced Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Unicancer

Dermatomyositis+4

Recruiting

Study on Upadacitinib for Patients with Idiopathic Inflammatory Myopathies After Stopping IVIG

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:Medical University Of Vienna

Neoplasm+1

Recruiting

Study of NVL-655 for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with ALK Mutation

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nvl-655
  • Sponsor:Nuvalent Inc.

Bronchiectasis

Recruiting

Study on the Effects of 7% Hypertonic Saline Inhalation and ELTGOL Physiotherapy for Patients with Bronchiectasis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Mannitol
  • Sponsor:Hospital Universitari De Girona Doctor Josep Trueta

Acute respiratory distress syndrome

Recruiting

Study of High-Dose Vitamin C (Ascorbic Acid) Compared to Placebo in Patients with Sepsis and Acute Respiratory Distress Syndrome (ARDS) in Intensive Care

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Ascorbate
  • Sponsor:Assistance Publique Hopitaux De Paris

Idiopathic pulmonary fibrosis

Recruiting

Study on the Effects of Methylprednisolone and Prednisone for Treating Acute Flare-Ups in Idiopathic Pulmonary Fibrosis Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:GIE Groupe hospitalier Paris Saint-Joseph/Vinci

Lymphoma+4

Recruiting

Study of OSE-279 and OSE2101 Drug Combination for Patients with Advanced Solid Tumors, Lymphomas, or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Imsidolimab
  • Sponsor:OSE Immunotherapeutics

Pleural mesothelioma malignant

Recruiting

Study on Adding Atezolizumab and WT1/DC Vaccine to Standard Treatment for Patients with Epithelioid Malignant Pleural Mesothelioma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Antwerp University Hospital

Infantile apnoea

Recruiting

Study on Doxapram for Treating Apnea in Preterm Newborns

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Doxapram Hydrochloride Monohydrate
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Metastases to central nervous system+1

Recruiting

Study on the Safety and Effectiveness of Repotrectinib for Patients with ROS1-Positive Non-Small Cell Lung Cancer and Active Brain Metastasis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Medica Scientia Innovation Research S.L.

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.